| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5478 | Vuf10166 Hydrochloride | Novel potent ligand at 5-HT3A and 5-HT3AB receptors with different activities |
|
| DCC5479 | Vuf10497 Featured | VUF10497 is a potent histamine H4 receptor (H4R) inverse agonist with anti-inflammatory activity. |
|
| DCC5480 | Vuf10499 | Potent human H4 receptor inverse agonist |
|
| DCC5481 | Vuf10558 | Highly Potent Human Histamine H4 Receptor Inverse Agonist |
|
| DCC5482 | Vuf11211 | Potent CXCR3 Antagonist, extending from the minor pocket into the major pocket of the transmembrane domains and binding between residues in helices 1 (Y1.39), 2 (W2.60), 3 (F3.32), 4 (D4.60), 6 (Y6.51), and 7 (S7.39, Y7.43) |
|
| DCC5483 | Vuf11222 | First reported nonpeptidomimetic agonist on The G protein-coupled chemokine receptor CXCR3 |
|
| DCC5484 | vuf14480 | Partial agonist in hH 4 R-mediated G protein signalling and β-arrestin2 recruitment, bounding covalently to the hH4R |
|
| DCC5485 | Vuf14738 | Novel robust and fatigue-resistant photoswitchable GPCR antagonist |
|
| DCC5486 | Vuf14862 | Novel robust and fatigue-resistant photoswitchable GPCR antagonist |
|
| DCC5487 | Vuf15259 | Novel inhibitor of Hbp secretion, activating σE stress, impairing Hbp secretion and decreasing the abundance of OMPs, consistent with impaired BAM function |
|
| DCC5488 | Vuf15888 | Novel photoswitchable modulator of the CXCR3 chemokine receptor |
|
| DCC5489 | Vuf16216 | Novel CXCR3 ligand, photoswitching from antagonism to agonism |
|
| DCC5490 | Vuf16620 | Novel photoswitchable modulator of the CXCR3 chemokine receptor |
|
| DCC5491 | vuf5228 | Histamine H3 receptor antagonist |
|
| DCC5492 | Vuf5391 | H3R inverse agonist |
|
| DCC5493 | vuf5455 | Adenosine A3 receptor (A3AR) allosteric modulator |
|
| DCC5494 | Vuf5834 | Novel full inverse agonist at CXCR3 N3.35A |
|
| DCC5495 | Vuf-6884 | Full agonist of hH4R with ~300-fold selectivity over hH3R and hH2R, but showing potent inverse agonistic activity at hH1R |
|
| DCC5496 | Vuf-8430 | Potent histamine H4 receptor full agonist |
|
| DCC5497 | Vuf8504 | Allosteric modulator of A3 adenosine receptors |
|
| DCC5498 | Biricodar(Vx-710) Featured | Biricodar (VX-710) is a multidrug resistance (MDR) modulator that targets two key drug efflux transporters: P-glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP-1). These transporters are often overexpressed in cancer cells and contribute to multidrug resistance (MDR) by pumping chemotherapeutic drugs out of the cells, reducing their intracellular concentration and efficacy. Biricodar inhibits the function of Pgp and MRP-1, effectively chemosensitizing multidrug-resistant cancer cells and enhancing the effectiveness of chemotherapy agents. Its ability to reverse MDR makes it a promising candidate for improving cancer treatment outcomes. |
|
| DCC5499 | Vzmc013 | Novel Probe of Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity |
|
| DCC5500 | w-13 Hydrochloride Featured | W-13 hydrochloride is a calmodulin antagonist. W-13 hydrochloride can inhibit Tamoxifen (HY-13757A)-resistant human breast cancer cell growth. |
|
| DCC5501 | w-5 Hydrochloride | Calmodulin antagonist, inhibiting Ca2+/calmodulin-regulated enzyme activities |
|
| DCC5502 | waladin1 | Mixed competitive/noncompetitive inhibitor of |
|
| DCC5503 | Wallichoside | Nocel inhibitor of BMI1 promoter activity, decreasing BMI1 protein levels in HCT116 human colon carcinoma cells, significantly reducing levels of the CSC biomarker epithelial cell adhesion molecule and diminishing the self-renewal capability of CSCs |
|
| DCC5504 | Way103 | Very late adhesion molecule 4 (VLA-4) antagonist, inhibiting VLA-4/VCAM-1 ligation as a means of modulating eosinophil functions beyond its action on cell adhesion and migration |
|
| DCC5505 | Way-123783 | SGLT2 inhibitor |
|
| DCC5506 | way-133537 | ATP-sensitive potassium channel opener |
|
| DCC5507 | Way-151693 | Inhibitor of human collagenase-3 (MMP-13) |
|
